Real‐world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis.

MLA

Yi, Jun Ho, et al. “Real‐world Outcomes of Ibrutinib Therapy in Korean Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Retrospective Analysis.” Cancer Communications, vol. 41, no. 3, Mar. 2021, pp. 275–78. EBSCOhost, https://doi.org/10.1002/cac2.12150.

APA

Yi, J. H., Kim, S. J., Yoon, D. H., Suh, C., Chang, M. H., Yang, D. H., Jo, J., Hyun, S. Y., Eom, H., Lee, J., Kwon, J. H., Han, S. H., Lee, S., Kwak, J., Kim, S. H., Kim, D. S., Lee, J. H., Oh, S. Y., Ryoo, H. M., & Kim, H. J. (2021). Real‐world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis. Cancer Communications, 41(3), 275–278. https://doi.org/10.1002/cac2.12150

Chicago

Yi, Jun Ho, Seok Jin Kim, Dok Hyun Yoon, Cheolwon Suh, Myung Hee Chang, Deok Hwan Yang, Jae‐Cheol Jo, et al. 2021. “Real‐world Outcomes of Ibrutinib Therapy in Korean Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Retrospective Analysis.” Cancer Communications 41 (3): 275–78. doi:10.1002/cac2.12150.